Mesalazine controlled release - Shire

Drug Profile

Mesalazine controlled release - Shire

Alternative Names: Lialda; MD-0901; Mesalamine oral - Shire Pharmaceutical Group; Mesalazine MMX™; Mesavance; Mesavancol; Mezavant; Mezavant XL; MMX Mesalamine; SPD 476

Latest Information Update: 15 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cosmo Pharmaceuticals
  • Developer Cosmo Pharmaceuticals; Mochida Pharmaceutical; Shire
  • Class Aminosalicylic acids; Anti-inflammatories; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ulcerative colitis
  • Discontinued Diverticulitis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Ulcerative-colitis(In adolescents, In children) in Australia (PO, Controlled release)
  • 01 Nov 2017 Mochida Pharmaceutical initiates enrolment in a phase II/III trial for ulcerative colitis (In children) in Japan (JapicCTI-173802)
  • 01 Nov 2017 Mochida Pharmaceutical initiates enrolment in a phase II/III trial for ulcerative colitis (In children) in Japan (JapicCTI-173803)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top